Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.

Muscle relaxants are used in the perioperative period to aid in endotracheal intubation, facilitate surgical exposure, and in the critical care setting for prolonged relaxation. Until now, the only mechanism to reverse their effect is acetylcholinesterase inhibitors that result in excess parasympathetic activity and require a second drug to prevent this side effect. Additionally, the onset and degree of neuromuscular antagonism are often unpredictable and unreliable. Sugammadex is the first of the cyclodextrins to be used as a therapeutic agent. It quickly, effectively, and safely reverses steroidal neuromuscular blockers by encapsulating the muscle relaxant and rendering it inactive. Sugammadex may be considered the ideal reversal agent and the first drug in its class, which will likely change the practice of anesthesia and clinical neuromuscular pharmacology.

[1]  C. Lien,et al.  Pharmacology of Muscle Relaxants and Their Antagonists , 2010 .

[2]  K. Candiotti,et al.  Reversal of Profound Neuromuscular Block by Sugammadex Administered Three Minutes after Rocuronium: A Comparison with Spontaneous Recovery from Succinylcholine , 2009, Anesthesiology.

[3]  J. Proost,et al.  Early Reversal of Profound Rocuronium-induced Neuromuscular Blockade by Sugammadex in a Randomized Multicenter Study: Efficacy, Safety, and Pharmacokinetics , 2007, Anesthesiology.

[4]  M. Naguib Sugammadex: another milestone in clinical neuromuscular pharmacology. , 2007, Anesthesia and analgesia.

[5]  P. White,et al.  Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with Neostigmine–Glycopyrrolate and Edrophonium–Atropine , 2007, Anesthesia and analgesia.

[6]  R. Soto,et al.  A Randomized, Dose-Finding, Phase II Study of the Selective Relaxant Binding Drug, Sugammadex, Capable of Safely Reversing Profound Rocuronium-Induced Neuromuscular Block , 2007, Anesthesia and analgesia.

[7]  A. Kopman Sugammadex: a revolutionary approach to neuromuscular antagonism. , 2006, Anesthesiology.

[8]  S. Ramael,et al.  First Human Exposure of Org 25969, a Novel Agent to Reverse the Action of Rocuronium Bromide , 2005, Anesthesiology.

[9]  A. Bom,et al.  Reversal of Neuromuscular Blockade and Simultaneous Increase in Plasma Rocuronium Concentration after the Intravenous Infusion of the Novel Reversal Agent Org 25969 , 2003, Anesthesiology.

[10]  Mark Bradley,et al.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. , 2002, Angewandte Chemie.

[11]  G. Gronert Cardiac Arrest after Succinylcholine: Mortality Greater with Rhabdomyolysis Than Receptor Upregulation , 2001, Anesthesiology.

[12]  P. White,et al.  Reversal of neuromuscular blockade. , 1998, Anesthesia and analgesia.

[13]  A. Kopman,et al.  Relationship of the Train‐of‐four Fade Ratio to Clinical Signs and Symptoms of Residual Paralysis in Awake Volunteers , 1997, Anesthesiology.

[14]  J. Proost,et al.  Early and late reversibility of rocuronium bromide. , 1994, European journal of anaesthesiology. Supplement.

[15]  M. Gitlin,et al.  Is mivacurium chloride effective in electroconvulsive therapy? A report of four cases, including a patient with myasthenia gravis. , 1993, Anesthesia and analgesia.

[16]  J. Norman Neuromuscular blocking drugs. , 1979, British journal of anaesthesia.